Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has released its financial results for the fourth quarter and year ended December 31, 2016. Amounts, unless specified otherwise, …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that its late-breaking abstract for voclosporin has been accepted for oral presentation at the National Kidney Foundation (NKF) …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares have been skyrocketing following the biotech firm’s major success with its Phase IIb trial evaluating voclosporin (VCS) …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are currently rising almost 8% after the biotech firm released the rare, good news that its drug in …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is on fire today with shares zooming up 66% in pre-market trading after the biotech firm’s drug voclosporin scored …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced on Monday that Richard Glickman would be taking on new roles as chairman and CEO of the firm …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) revealed yesterday evening that its Board of Directors has chosen Dr. Richard Glickman, the biotech firm’s founder and Chairman, …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its Board of Directors has appointed Dr. Richard M.
